Supplemental data

Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from pivotal phase II CheckMate 205 study

Supplemental Table 1. Disease status after subsequent allo-HCT	Cohort A (BV-naive) (n = 13)	Cohort B (BV after auto-HCT) (n = 14)	Cohort C (BV before and/or after auto-HCT) (n = 30)	Overall (N = 57)
CR, n (%)[a]				
At allo-HCT	6 (46.2)	7 (50.0)	13 (43.3)	26 (45.6)
100 days	8 (61.5)	11 (78.6)	14 (46.7)	33 (57.9)
6 months	7 (53.8)	11 (78.6)	16 (53.3)	34 (59.6)
1 year	8 (61.5)	12 (85.7)	14 (46.7)	34 (59.6)
2 years	7 (53.8)	9 (64.3)	13 (43.3)	29 (50.9)
PR, n (%)[a]				
At allo-HCT	6 (46.2)	6 (42.9)	10 (33.3)	22 (38.6)
100 days	2 (15.4)	2 (14.3)	3 (10.0)	7 (12.3)
6 months	0	1 (7.1)	2 (6.7)	3 (5.3)
1 year	0	1 (7.1)	3 (10.0)	4 (7.0)
2 years	0	0	1 (3.3)	1 (1.8)
SD, n (%)[a]				
At allo-HCT	0	1 (7.1)	0	1 (1.8)
100 days	1 (7.7)	0	0	1 (1.8)
6 months	1 (7.7)	1 (7.1)	0	2 (3.5)
1 year	0	0	0	0

2 years	0	0	0	0
PD, n (%)[a]				
At allo-HCT	0	0	0	0
100 days	0	0	1 (3.3)	1 (1.8)
6 months	0	0	2 (6.7)	2 (3.5)
1 year	0	0	2 (6.7)	2 (3.5)
2 years	0	0	0	0
Median time from last nivolumab dose to allo-HCT, days (range)	170.0 (27–418)	42.5 (23–273)	55.0 (16–716)	63.0 (16–716)

Allo-HCT, allogeneic hematopoietic cell transplantation; BV, brentuximab vedotin; CR, complete remission; PD, progressive disease; PR, partial remission; SD, stable disease.

[a]Response data were not available or able to be determined for all patients at each time point, but percentages are calculated out of the total number of patients who received allo-HCT in a given cohort, regardless of whether response data were available.

Supplemental Table 2. Baseline demographics and disease characteristics for patients who achieved persistent complete response in cohort C

Characteristic[a]	Discontinued nivolumab after persistent CR (n = 12)	Cohort C overall (n = 100)
Age, median (range), years	45 (22–53)	32 (19–69)
Female	8 (66.7)	44 (44.0)
Stage at study entry		
I	1 (8.3)	2 (2.0)
II	3 (25.0)	20 (20.0)
III	2 (16.7)	17 (17.0)
IV	6 (50.0)	61 (61.0)
B symptoms at study entry	3 (25.0)	25 (25.0)
Bulky disease at study entry	5 (41.7)	22 (22.0)
Extralymphatic involvement	2 (16.7)	45 (45.0)
Time from diagnosis to first dose of nivolumab, median (IQR), years	4.4 (2.5–11.9)	3.5 (2.3–6.4)

CR, complete remission; IQR, interquartile range.

[a]All values are n (%) unless otherwise indicated.

Supplemental Figure 1: Patient disposition (CONSORT diagram)



AE, adverse event; HCT, hematopoietic cell transplantation.

[a]Reasons include auto-HCT (n = 34); patient, physician, or investigator decision (n = 7); patient received nivolumab at home (n = 1); patient returned to home country (n = 1); secondary neoplasia (n = 1); and transformation to diffuse large B-cell lymphoma (n = 1).